Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus–associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002856
Abstract: Anti–interferon-γ monoclonal antibody emapalumab and JAK1/2 inhibitors ruxolitinib have been widely reported for the treatment of hemophagocytic lymphohistiocytosis (HLH) recently. These targeted drugs have fewer side effects and may provide new options for patients with… read more here.
Keywords: treatment; epstein barr; emapalumab ruxolitinib; ruxolitinib dexamethasone ... See more keywords